RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

Search

Houlihan Lokey Inc

Închisă

SectorFinanțe

143.37 1.39

Rezumat

Modificarea prețului

24h

Curent

Minim

140.71

Maxim

145.19

Indicatori cheie

By Trading Economics

Venit

4.8M

117M

Vânzări

58M

717M

P/E

Medie Sector

21.537

54.484

Randament dividend

1.7

Marjă de profit

16.253

Angajați

2,702

EBITDA

-10M

169M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+44.24% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.70%

4.92%

Următoarele câștiguri

6 mai 2026

Data viitoare de dividende

12 iun. 2026

Următoarea dată ex-dividende

1 iun. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-3B

9.8B

Deschiderea anterioară

141.98

Închiderea anterioară

143.37

Sentimentul știrilor

By Acuity

83%

17%

403 / 441 Clasament în Finance

Houlihan Lokey Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Nike, RH, NCino

31 mar. 2026, 22:35 UTC

Câștiguri

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr. 2026, 00:00 UTC

Achiziții, Fuziuni, Preluări

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar. 2026, 23:50 UTC

Achiziții, Fuziuni, Preluări

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar. 2026, 23:21 UTC

Câștiguri

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar. 2026, 23:14 UTC

Market Talk
Câștiguri

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar. 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss Widens >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar. 2026, 21:46 UTC

Achiziții, Fuziuni, Preluări

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar. 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar. 2026, 21:33 UTC

Achiziții, Fuziuni, Preluări

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar. 2026, 21:33 UTC

Câștiguri

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar. 2026, 21:32 UTC

Câștiguri

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar. 2026, 21:28 UTC

Câștiguri

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar. 2026, 21:26 UTC

Câștiguri

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar. 2026, 21:25 UTC

Câștiguri

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar. 2026, 21:24 UTC

Market Talk
Câștiguri

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar. 2026, 21:22 UTC

Câștiguri

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar. 2026, 21:22 UTC

Câștiguri

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar. 2026, 21:21 UTC

Câștiguri

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar. 2026, 21:20 UTC

Câștiguri

Nike CEO: Converse Remains Important to Portfolio

Comparație

Modificare preț

Houlihan Lokey Inc Așteptări

Obiectiv de preț

By TipRanks

44.24% sus

Prognoză pe 12 luni

Medie 200.5 USD  44.24%

Maxim 214 USD

Minim 163 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHoulihan Lokey Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

4

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

403 / 441 Clasament în Finanțe

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Houlihan Lokey Inc

Houlihan Lokey, Inc., an investment banking company, provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services in the United States and internationally. It operates in three segments: Corporate Finance (CF), Financial Restructuring (FR), and Financial and Valuation Advisory (FVA). The CF segment offers general financial advisory services; and advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions, as well as financial sponsors on various transactions. The FR segment advises debtors, creditors, and other parties-in-interest related to recapitalization/deleveraging transactions. This segment also provides a range of advisory services, including structuring, negotiation, and confirmation of plans of reorganization; structuring and analysis of exchange offers; corporate viability assessment; dispute resolution and expert testimony; and procuring debtor-in-possession financing. The FVA segment offers valuations of various assets, such as companies, illiquid debt and equity securities, and intellectual property; and dispute resolution services. This segment also provides fairness opinions in connection with M&A and other transactions, solvency opinions in connection with corporate spin-offs and dividend recapitalizations, and other types of financial opinions. The company serves corporations, financial sponsors, and government agencies. Houlihan Lokey, Inc. was incorporated in 1972 and is headquartered in Los Angeles, California.
help-icon Live chat